RIO DE JANEIRO, BRAZIL - With 7,000 square meters thanks to the public and private contribution, the University of Chile, together with the Italian pharmaceutical company Reithera are promoting the construction of the space in the Carén Park that belongs to the university to develop there the vaccine of the European company that today is in the phase of verification or Phase 3 by the authorities of that country.
Read also: Check out our coverage on Chile
The company's executives hope that the building will have the same characteristics as the one in Rome, where research will also . . .